[go: up one dir, main page]

BRPI0511126A - métodos de tratamento utilizando proteìnas de ligação de albumina como alvos - Google Patents

métodos de tratamento utilizando proteìnas de ligação de albumina como alvos

Info

Publication number
BRPI0511126A
BRPI0511126A BRPI0511126-9A BRPI0511126A BRPI0511126A BR PI0511126 A BRPI0511126 A BR PI0511126A BR PI0511126 A BRPI0511126 A BR PI0511126A BR PI0511126 A BRPI0511126 A BR PI0511126A
Authority
BR
Brazil
Prior art keywords
chemotherapeutic agent
targets
treatment methods
binding proteins
albumin binding
Prior art date
Application number
BRPI0511126-9A
Other languages
English (en)
Inventor
Vuong Trieu
Neil P Desai
Patrick Soon-Shiong
Original Assignee
Abraxis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35463351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0511126(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abraxis Bioscience Inc filed Critical Abraxis Bioscience Inc
Publication of BRPI0511126A publication Critical patent/BRPI0511126A/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

MéTODOS DE TRATAMENTO UTILIZANDO PROTEìNAS DE LIGAçãO DE ALBUMINA COMO ALVOS A invenção provê um método para determinar a sensibilidade de um tumor de mamífero a um agente quimioterapêutico compreendendo detecção e quantificação da proteína SPARC em uma amostra isolada do ser humano. A Invenção também provê um método para distribuição de um agente quimioterapêutico a um tumor em um ser humano que expressa SPARC compreendendo administração de uma composição farmacêutica compreendendo o agente quimioterapêutico acoplado a um composto que se liga à proteína SPARC. A invenção provê, adicionalmente, uma composição compreendendo um agente quimioterapêutico acoplado a um composto capaz de ligação à proteína SPARC e um veículo farmaceuticamente aceitável.
BRPI0511126-9A 2004-05-14 2005-05-16 métodos de tratamento utilizando proteìnas de ligação de albumina como alvos BRPI0511126A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57162204P 2004-05-14 2004-05-14
US65426105P 2005-02-18 2005-02-18
PCT/US2005/017174 WO2005117952A2 (en) 2004-05-14 2005-05-16 Treatment methods utilizing albumin-binding proteins as targets

Publications (1)

Publication Number Publication Date
BRPI0511126A true BRPI0511126A (pt) 2007-11-27

Family

ID=35463351

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511126-9A BRPI0511126A (pt) 2004-05-14 2005-05-16 métodos de tratamento utilizando proteìnas de ligação de albumina como alvos

Country Status (8)

Country Link
EP (3) EP3327031A1 (pt)
JP (1) JP4689666B2 (pt)
CN (2) CN102614521A (pt)
BR (1) BRPI0511126A (pt)
CA (1) CA2566571A1 (pt)
ES (2) ES2529660T3 (pt)
MX (1) MXPA06013191A (pt)
WO (1) WO2005117952A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1585548T (lt) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
EP1869077A2 (en) * 2005-02-18 2007-12-26 Abraxis BioScience, Inc. Q3 sparc deletion mutant and uses thereof
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
HUE038768T2 (hu) 2005-02-18 2018-11-28 Abraxis Bioscience Llc Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia
EP2035830B1 (en) * 2006-06-14 2015-03-25 Johns Hopkins University Albumin-bound protein/peptide complex as a biomarker for disease
BRPI0808635B1 (pt) * 2007-03-07 2022-06-07 Abraxis Bioscience, Llc Uso de uma composição farmacêutica compreendendo nanopartículas que compreendem rapamicina ou um seu derivado e uma proteína veículo, composição para uso em um método de tratamento de câncer em um indivíduo, forma de dosagem unitária para o referido tratamento, e kit
AU2015271950B2 (en) * 2007-03-07 2017-09-28 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
AU2013204187B2 (en) * 2007-03-07 2015-10-01 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
CA2683973A1 (en) * 2007-04-13 2008-10-23 Abraxis Bioscience, Inc. Sparc and methods of use thereof
ES2435452T3 (es) 2007-06-01 2013-12-19 Abraxis Bioscience, Llc Métodos y composiciones para tratar un cáncer recurrente
WO2010065950A2 (en) * 2008-12-05 2010-06-10 Abraxis Bioscience, Llc Albumin binding peptide-mediated disease targeting
MX2011005967A (es) 2008-12-05 2011-06-30 Abraxis Bioscience Llc Peptidos enlazados a sparc y usos de los mismos.
EP2544704A4 (en) * 2010-03-11 2013-08-28 Abraxis Bioscience Llc SPARC ANGIOGENIC DOMAIN AND METHODS OF USE
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
WO2011137441A2 (en) * 2010-04-30 2011-11-03 Abraxis Bioscience, Llc Sparc binding aptamers and uses thereof
KR20130108104A (ko) * 2010-06-03 2013-10-02 아브락시스 바이오사이언스, 엘엘씨 말초혈 ｓｐａｒｃ 결합 항체와 이들의 용도
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
EP3074047A2 (en) * 2013-11-26 2016-10-05 The Brigham and Women's Hospital, Inc. Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery
CN113318239B (zh) * 2014-06-13 2025-05-30 梅约医药教育及研究基金会 治疗淋巴瘤
KR20230006037A (ko) * 2016-08-05 2023-01-10 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료를 위한 변형된 항체-알부민 나노입자 복합체
CN106755499B (zh) * 2017-01-24 2020-06-30 青岛市畜牧兽医研究所 一种与奶山羊乳体细胞数性状相关的分子标记及其应用
EP3866834A1 (en) * 2018-10-17 2021-08-25 Sunstate Biosciences, LLC Single protein-encapsulated pharmaceutics for enhancing therapeutic effects
JP7466875B2 (ja) * 2021-02-19 2024-04-15 ソウル大学校産学協力団 Ｓｐａｒｃを発現する癌の治療用組成物
CN113842387A (zh) * 2021-11-19 2021-12-28 大连理工大学盘锦产业技术研究院 10-羟基喜树碱与鹰嘴豆芽素a的药物组合物及其应用
CN118086317B (zh) * 2024-01-12 2025-03-25 深圳市第二人民医院(深圳市转化医学研究院) Sparc蛋白基因调控元件、功能化白蛋白纳米制剂及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US20040018188A9 (en) * 1999-01-20 2004-01-29 Incyte Genomics, Inc. Sparc-related proteins
KR20020012292A (ko) * 1999-06-25 2002-02-15 제넨테크, 인크. 항-ＥｒｂＢ 항체-메이탄시노이드 결합체를 사용한 치료방법
CN1240721C (zh) * 2002-12-03 2006-02-08 中国医学科学院医药生物技术研究所 力达霉素与单克隆抗体及其Fab'片段的偶联物以及在结肠癌等肿瘤靶向治疗中的应用
EP2233926A3 (en) * 2003-04-01 2011-01-12 The Johns Hopkins University Breast Endothelial Cell Expression Patterns
ES2394799T3 (es) * 2003-12-31 2013-02-05 The Penn State Research Foundation Métodos para predecir y superar la resistencia a quimioterapia en cáncer de ovario

Also Published As

Publication number Publication date
EP1755653A2 (en) 2007-02-28
EP2784082B1 (en) 2017-12-27
EP2784082A1 (en) 2014-10-01
ES2529660T3 (es) 2015-02-24
EP1755653B1 (en) 2014-12-31
WO2005117952A2 (en) 2005-12-15
CN102614521A (zh) 2012-08-01
JP2007537460A (ja) 2007-12-20
JP4689666B2 (ja) 2011-05-25
EP1755653A4 (en) 2008-09-03
WO2005117952A3 (en) 2006-04-13
CN1980699B (zh) 2012-03-21
CN1980699A (zh) 2007-06-13
MXPA06013191A (es) 2007-07-24
EP3327031A1 (en) 2018-05-30
ES2662848T3 (es) 2018-04-10
CA2566571A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
BRPI0511126A (pt) métodos de tratamento utilizando proteìnas de ligação de albumina como alvos
Cantley et al. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Jensen et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
Salazar et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells
Manza et al. Global shifts in protein sumoylation in response to electrophile and oxidative stress
Tohidnezhad et al. Role of platelet-released growth factors in detoxification of reactive oxygen species in osteoblasts
Spenlé et al. Tenascin-C: Exploitation and collateral damage in cancer management
Heijnen et al. Subcellular localization of tyrosine-nitrated proteins is dictated by reactive oxygen species generating enzymes and by proximity to nitric oxide synthase
Zhang et al. MG53 participates in ischaemic postconditioning through the RISK signalling pathway
Guenter et al. Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment
Kim et al. Status epilepticus induces vasogenic edema via tumor necrosis factor-α/endothelin-1-mediated two different pathways
WO2009085216A3 (en) Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
Wu et al. Salvianolic acid B protects human endothelial cells from oxidative stress damage: a possible protective role of glucose-regulated protein 78 induction
BRPI0416603A (pt) anticorpo que se liga ao receptor interleucina-4 (il-4) humano
BRPI0622054B8 (pt) composto e composição farmacêutica
Wollina Cutaneous T cell lymphoma: update on treatment
Russo et al. A Cyclin D2-derived peptide acts on specific cell cycle phases by activating ERK1/2 to cause the death of breast cancer cells
Makanga et al. Towards a proteomic definition of CoArtem action in Plasmodium falciparum malaria
Johnson et al. The deadly connection between endoplasmic reticulum, Ca2+, protein synthesis, and the endoplasmic reticulum stress response in malignant glioma cells
Schrickx et al. Danofloxacin‐mesylate is a substrate for ATP‐dependent efflux transporters
Narayan et al. Identification and quantitative analysis of cellular proteins affected by treatment with withaferin a using a SILAC-based proteomics approach
MX2022001756A (es) Inhibidor del punto de control inmunitario, agente terapeutico para la enfermedad relacionada con el punto de control inmunitario, inmunosupresor, anticuerpo contra la fibronectina o derivado del mismo, analogo de la fibronectina, kit para detectar la fibronectina o una proteina parcial de la misma, y metodo para detectar la fibronectina o una proteina parcial de la misma.
Bajraktari et al. Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets
BR112013023978A2 (pt) "polipeptídeo com afinidade por proteínas de choque térmico e seu uso em diagnóstico de doença infecciosa, produção de resposta imune e tratamento 5 de câncer, bem como ácido nucleico, composição e método de fracionamento de substância para pesquisa ou análise clínica de amostra biológica".
Parks et al. Autophagic flux inhibition and lysosomogenesis ensuing cellular capture and retention of the cationic drug quinacrine in murine models

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 12A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents)